临床试验/NCT05001516

NCT05001516已完成1 期

A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of TPX4589 in Patients With Claudin(CLDN)18.2-Positive Advanced Solid Tumors

Turning Point Therapeutics, Inc.7 个研究点分布在 1 个国家目标入组 17 人开始时间: 2021年12月29日最近更新: 2024年4月17日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Turning Point Therapeutics, Inc.
入组人数: 17
试验地点: 7
主要终点: Dose limiting toxicity (DLT)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors

详细描述

A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors

The study schedule includes screening visit (28 days prior to accept the investigational medicinal product (IMP)), treatment visit (accept IMP for the first time to the end of treatment (EOT)/early withdrawal), and follow-up visit (28 days after the EOT/early withdrawal).

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Sequential
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Subjects who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure;
•Aged ≥18 years old when sign the ICF, male or female;
•Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and no deterioration within 2 weeks prior to the first dose;
•Life expectancy ≥ 3 months;
•Phase Ⅰa (Dose Escalation): Subjects must have histological or cytological confirmation of recurrent or refractory advanced solid tumors, and have progressed on standard therapy, or are intolerable for available standard therapy , or there is no available standard therapy. The advanced solid tumors include but not limit to gastric and gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, pancreatic carcinoma, biliary tract carcinoma, colorectal carcinoma, ovarian carcinoma.
•Claudin18.2(CLDN18.2) status will be tested by central immunohistochemistry (IHC) testing for the enrolled subjects if the archived tumor tissue samples are available, and the enrolment is not dependent on the CLDN18.2's status.
•CLDN18.2 positive may be required for the high dose levels as determined by Safety Monitoring Committee(SMC), the subjects need to have CLDN 18.2 positive available before enrolled and dosed, and the tumor types are limited to the types listed as phase Ib (Dose expansion).
•Phase Ib (Dose Expansion): Subjects must have histological or cytological confirmation of recurrent or refractory CLDN18.2 positive* advanced solid tumors, and have progressed on standard therapy, or are intolerable for available standard therapy , or there is no available standard therapy. The advanced solid tumors include the following or the specific tumor types that are determined by SMC:
•Gastric and gastroesophageal junction adenocarcinoma;
•Pancreatic carcinoma;
•Biliary tract carcinoma;
•Colorectal carcinoma with known Microsatellite instability-high(MSI-H)/Different Mismatch Repair(dMMR);
•Esophageal adenocarcinoma;
•Ovarian mucinous carcinoma;
•*CLDN18.2-positive: defined as CLDN18.2 expression confirmed by central immunohistochemistry (IHC) test and with a staining intensity of 1+ to 3+ in ≥ 10% of the tumor cell. At least 3 subjects with a staining intensity of 2+ to 3+ in ≥ 40% of the tumor cells should be included for the dose expansion stage.
•At least one evaluable lesion (including measurable and unmeasurable) for phase Ia dose escalation, and one measurable lesion for phase Ib dose expansion, according to RECIST v1.1;
•Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose:
•Bone marrow reserve: Platelet count (PLT) ≥ 90 × 109/L; Absolute neutrophil count (ANC) ≥ 1.5 × 109/L; Haemoglobin ≥ 9 g/dL, without receiving Erythropoietin(EPO), G-Colony-Stimulating Factor(CSF), or Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) within 14 days and blood transfusion including red blood cell and platelet transfusion in at least 7 days prior to first dose;
•Coagulation function: International Normalized Ratio(INR) ≤ 1.5; Activated Partial Thromboplastin Time(APTT) ≤ 1.5 × ULN;
•Liver function: Total bilirubin ≤ 1.5 × ULN (Subjects with Gilbert's Syndrome are allowed if total bilirubin ≤ 3 × ULN); Aspartate Transaminase(AST) and Alanine Aminotransferase(ALT) ≤ 2.5 × ULN without liver metastases (≤ 5 × ULN if liver metastases are present); Albumin ≥ 2.5 g/dL;
•Kidney function: Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min (using Cockcroft-Gault formula);
•Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50%; QT interval (QTcF) ≤ 480 ms;
•Subjects who are able to communicate we

排除标准

•Exposure to any IMP, or participate in any other clinical trial within 21 days prior to 1st dosing of LM-302;
•Subjects with anti-tumor treatment within 21 days prior to 1st dosing of LM-302, including radiotherapy, chemotherapy, biotherapy, endocrine therapy and immunotherapy, etc. Following treatments have different time limits:
•Local small-scale palliative radiotherapy (bone metastasis radiotherapy to control pain) within 14 days prior to 1st dosing;
•Oral anti-tumor therapy, including fluorouracil antitumor drugs and small molecular targeted drugs, etc. within 14 days or 5 half-life of the drug (whichever is shorter) prior to 1st dosing;
•Traditional Chinese medicine with anti-tumor indication within 14 days prior to 1st dosing.
•Nitrosourea or Mitomycin C within 42 days prior to 1st dosing.
•Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0 (Except for toxicities without safety risk judged by the investigator, such as alopecia, and other ≤ grade 2 long term toxicities);
•Pre-existing peripheral sensory or motor neuropathy ≥ Grade 2;
•Subjects with uncontrolled tumor-related pain. Subjects requiring analgesic treatment must be on a stable regimen before participating in the study. Symptomatic lesions amenable by palliative radiotherapy (e.g., bone metastases or metastases causing nerve damage) should be treated prior to enrolment. For the asymptomatic metastatic lesions whose further growth would likely cause functional defects or intractable pain, if appropriate, local treatment should be considered before enrolment;
•Subjects with known central nervous system (CNS) or meningeal metastasis;
•Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures;
•Subjects who are allergic or hypersensitive to LM-302 (The excipients are L-Glutamic acid, L-Arginine, Trehalose dihydrate and polysorbate 80 (for injection)) or similar products;
•Subjects who have received the treatment targeting to CLDN18.2 or Monomethyl Auristatin E(MMAE) based Antibody-Drug Conjugates (ADCs):
•Subjects who have received the treatment with ADCs targeting to CLDN18.2 are not eligible;
•Subjects who were intolerable to the treatment with MMAE based ADCs or anti-CLDN18.2 antibodies are not eligible, but can be enrolled if they were tolerable to the treatments and have experienced a 28-day's washout period prior to 1st dosing of LM-302;
•For Phase Ib (Dose Expansion), subjects who were not response to the treatment with MMAE based ADCs or anti-CLDN18.2 antibodies are not eligible;
•Administrate strong inhibitors/strong inducers of CYP3A4 within 14 days prior to 1st dosing of LM-302;
•Subjects with known active keratitis or corneal ulcerations. Subjects with superficial punctate keratitis are allowed if the disorder is being adequately treated in the opinion of the investigator.
•Use of any live vaccines (e.g., against infectious diseases such as influenza, varicella, COVID-19, etc.) within 28 days prior to 1st dosing of LM-302;
•Subjects with the history of interstitial lung disease or drug-induced interstitial lung disease/pneumonitis;
•Subjects who are taking therapeutic doses of anticoagulants such as heparin or vitamin K antagonists (except for preventive treatment at a stable dose);
•Subjects with gastric outlet obstruction, persistent recurrent vomiting or uncontrolled/severe gastrointestinal hemorrhage, or ulcer within 28 days prior to 1st dosing of LM-302;
•Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-302 (excluding tumor biopsy, puncture, etc.);
•Subjects who have other active malignancies which are likely to require the treatment;
•Subjects who have severe cardiovascular disease, including but not limited to:
•Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, and II-III degree atrioventricular block, etc.;
•Thromboembolic events requiring therapeutic anticoagulation, or equipped with venous filters;
•Cardiac insufficiency of grade III~IV according to the New York Heart Association (NYHA) standards;
•Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other cardiovascular and cerebrovascular events of grade 3 or above occurred within 6 months prior to 1st dosing of LM-302;
•Clinically uncontrollable hypertension;
•Subjects who have uncontrolled or severe illness, including but not limited to ongoing or active infection (e.g., active Corona Virus Disease 2019（COVID-19）/Severe Acute Respiratory Syndromes(SARS)-COVID-2 infection, etc.) requiring antibiotics and/or other therapeutic administration, while SARS-COVID-2 testing is not mandatory for study entry, and the testing should follow local clinical practice guidelines/standards.
•Subjects who have a history of immunodeficiency disease, including other acquired or congenital immunodeficiency diseases, or organ transplantation, or allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation;
•HIV infection, active Hepatitis B Virus(HBV) and Hepatitis C Virus(HCV)infection, with the exception:
•Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-hepatitis B core(HBc)] and absence of HBsAg), as well as with normal liver function are eligible. Otherwise, if HBV infection was indicated, those with HBV DNA < 500 IU/ML (or equivalent level) and normal liver function, combined with clinical manifestations, judged by the investigator to exclude active infection can be enrolled;
•Subjects with positive HCV antibody but negative hepatitis C virus RNA test results and normal liver function are eligible.
•Child-bearing potential female who have positive results in pregnancy test or are lactating;
•Subjects who have psychiatric illness or disorders that may preclude study compliance;
•Subject who is judged as not eligible to participate in this study by the investigator.

研究组 & 干预措施

LM302 Dose Escalation Level 1, 0.2 mg/kilogram(kg),

Experimental

The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.

first dose: 0.2mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=1;

干预措施: LM-302 (Drug)

LM302 Dose Escalation Level 2, 0.4 mg/kg

Experimental

The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.

second dose: 0.4mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=3;

干预措施: LM-302 (Drug)

LM302 Dose Escalation Level 3, 0.8 mg/kg

Experimental

The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.

third dose: 0.8mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;

干预措施: LM-302 (Drug)

LM302 Dose Escalation Level 4, 1.6mg/kg

Experimental

The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.

fourth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;

干预措施: LM-302 (Drug)

LM302 Dose Escalation Level 5, 2.4mg/kg

Experimental

The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.

fifth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=9;

干预措施: LM-302 (Drug)

LM302 Dose Escalation Level 6, 2.8mg/kg

Experimental

The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.

sixth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=12;

干预措施: LM-302 (Drug)

结局指标

主要结局

Dose limiting toxicity (DLT)

时间窗: Cycle 1 of each cohort. Duration of one cycle is 21 days

DLT is defined as a toxicity (adverse event at least possibly related to LM302) occurring during the DLT observation period

Change in Vital Signs-ear temperature